Stabilization announcement - Karolinska Development AB share
STOCKHOLM - May 18, 2011. The stabilization period in conjunction with the IPO of Karolinska Development AB commenced on April 15, 2011 and was concluded on May 13, 2011. During the period, stabilization acquisitions occurred totalling 1,710,000 shares, corresponding to 15 percent of the base offering of 11,400,000 shares in Karolinska Development AB. All of the stabilization transactions were conducted in the price range of SEK 35.80-40.00. The stabilization period has now been concluded and no further stabilization transactions will be conducted.
Range per day
April 15, 2011: SEK 39.90 - SEK 40.00
April 18, 2011: SEK 39.50 - SEK 40.00
April 19, 2011: SEK 37.60 - SEK 39.50
April 20, 2011: SEK 37.50 - SEK 39.00
April 21, 2011: SEK 39.50 - SEK 39.50
April 26, 2011: SEK 38.10 - SEK 39.00
April 27, 2011: SEK 38.00 - SEK 38.50
April 28, 2011: SEK 37.90 - SEK 38.00
April 29, 2011: SEK 37.50 - SEK 37.70
May 02, 2011: SEK 37.20 - SEK 38.00
May 03, 2011: SEK 37.70 - SEK 38.00
May 04, 2011: SEK 37.50 - SEK 38.00
May 05, 2011: SEK 37.60 - SEK 37.90
May 06, 2011: SEK 37.20 - SEK 38.00
May 09, 2011: SEK 37.30 - SEK 38.70
May 10, 2011: SEK 37.80 - SEK 38.80
May 11, 2011: SEK 37.50 - SEK 39.00
May 12, 2011: SEK 35.80 - SEK 37.70
May 13, 2011: SEK 36.80 - SEK 38.50
A total of 1,710,000 shares in Karolinska Development AB, which were on loan to cover any over-allotment in conjunction with the company's IPO, will be returned to the shareholders concerned today, May 18, 2011.
SEB Enskilda was Lead Manager in conjunction with the IPO.
For further information, please contact:
Torbjörn Bjerke, CEO Karolinska Development AB
Phone: +46 (0)72 744 41 23, e-mail: torbjorn.bjerke@karolinskadevelopment.com
Gunnar Casserstedt, CFO Karolinska Development AB
Phone: +46 (0)73 068 37 00, e-mail: gunnar.casserstedt@karolinskadevelopment.com
TO THE EDITORS
About Karolinska Development
Karolinska Development aims to create value for investors, patients, and researchers by developing innovations from world class research into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP these to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out licensing of products. This will result in upfront payments, milestone payments and royalties.
An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading Nordic universities, delivers a continuous flow of innovations.
Karolinska Development's flexible exit strategy enables projects to be exited at whichever stage of development offers the greatest return on investment, usually after Phase II clinical trials have indicated the desired pharmaceutical effect on patients - this being an important value enhancing step.
Today, the portfolio consists of over 40 projects at various stages, from concept development to Phase II clinical trials, twelve projects are in clinical trials with six in Phase II. The portfolio is particularly strong in the areas of cancer, dermatology, inflammation, cardiovascular disease, women's health and diseases that affect the central nervous system. www.karolinskadevelopment.com